Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB-Related Articles										Related Pages
										**Journal Articles Published by Division of TB Elimination (DTBE) Authors**
**2014 DTBE journal articles**
Anderson L, Tollefson D, Bloss E, Armstrong L, Yelk Woodruff R, van den Hof S. Chapter 3. Analysis of genotyping data and outbreak investigations. In: Understanding and Using Tuberculosis Data. Luxembourg: WHO; 2014. WHO/HTM/TB/2014.09.
Baker BJ, Jeffries CD, Moonan PK. Decline in tuberculosis among Mexico-born persons in the United Statesexternal icon, 2000-2010. Ann Am Thorac Soc 2014 May;11(4):480-8. doi:10.1513/AnnalsATS.201402-065OC.Year202120202019201820172016201520142013Baker BJ, Moonan PK. Characterizing tuberculosis genotype clusters along the United States–Mexico border. [Short communication.] The International Journal of Tuberculosis and Lung Diseaseexternal icon 2014 March 1; 18 (3): 289-291.
Bamrah S, Brostrom R, Dorina F, Setik L, Song R, Kawamura LM, Heetderks A, Mase S. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012. Int J Tuberc Lung Dis 2014 18(8):912–918. http://dx.doi.org/10.5588/ijtld.13.0028
Bamrah S, Desmond E, Ghosh S, France AM, Kammerer JS, Cowan LS, Heetderks A, Forbes A, Moonan PK. Molecular epidemiology of *Mycobacterium tuberculosis* in the United States-affiliated Pacific Islands. Asia Pac J Public Health 2014 Jan; 26(1):77-84. http://journals.sagepub.com/doi/full/10.1177/1010539512469249external icon
Bansal AK, Kulshrestha N, Nagaraja SB, Rade K, Choudhary A, Parmar M, Nair SA, Dewan PK, Yadav R, Moonan PK. Composite indicator: new tool for monitoring RNTCP performance in India. Int J Tuberc Lung Dis 2014 Jul;18(7):840-2. www.ncbi.nlm.nih.gov/pubmed/24902562external icon
Berzkalns A, Bates J, Ye W, Mukasa L, France AM, et al. The road to tuberculosis (*Mycobacterium tuberculosis*) elimination in Arkansas; a re-examination of risk groups. PLoS One 2014; 9(3): e90664. doi:10.1371/journal.pone.0090664.
Bharaswadkar S, Kanchar A, Thakur N, Shah S, Patnaik B, Click ES, Kumar AM, Dewan PK. Tuberculosis management practices of private practitioners in Pune Municipal Corporation, India. PLoS One 2014; 9(6): e97993. doi:10.1371/journal.pone.0097993.
Blaya JA, Shin SS, Yagui M, Contreras C, Cegielski P, Yale G, Suarez C, Asencios L, Bayona J, Kim J, Fraser HS. Reducing communication delays and improving quality of care with a tuberculosis laboratory information system in resource poor environments: a cluster randomized controlled trial.external icon PLoS One 2014 Apr 10;9(4):e90110. doi: 10.1371/ journal.pone.0090110.
Bloss E, Ershova J, van den Hof S, Law I, Mitchell E, Tollefson D. Chapter 1. Analysis of aggregated tuberculosis notification data. In: Understanding and Using Tuberculosis Data. Luxembourg: WHO; 2014. WHO/HTM/TB/2014.09.
Bloss E, Yelk Woodruff R, Tollefson D, van den Hof S, Armstrong L, Anderson L. Chapter 2. Analysis of case-based TB notification data. In: Understanding and Using Tuberculosis Data. Luxembourg: WHO; 2014. WHO/HTM/TB/2014.09.
CDC (Alami NN, Yuen CM, Miramontes R, Pratt R, Price SF, Navin TR.) Trends in tuberculosis – United States, 2013. MMWR 2014 Mar 21; 63(11): 229-33.
CDC (Borchert JN, Tappero JW, Downing R, Shoemaker T, Behumbiize P, Aceng J, Makumbi I, Dahlke M, Jarrar B, Lozano B, Kasozi S, Austin M, Phillippe D, Watson ID, Evans TJ, Stotish T, Dowell SF, Iademarco MF, Ransom R, Balajee A, Becknell K, Beauvais D, Wuhib T.) Rapidly building global health security capacity – Uganda demonstration project, 2013. MMWR 2014 Jan 31;63(4):73-6.
CDC (Richardson-Smith N.) World TB Day — March 24, 2014 . MMWR 2014 Mar 21;63 (11):229.
CDC (Tran PD, Vu LN, Nguyen HT, Phan LT, Lowe W, McConnell MS, Iademarco MF, Partridge JM, Kile JC, Do T, Nadol PJ, Bui H, Vu D, Bond K, Nelson DB, Anderson L, Hunt KV, Smith N, Giannone P, Klena J, Beauvais D, Becknell K, Tappero JW, Dowell SF, Rzeszotarski P, Chu M, Kinkade C.) Strengthening global health security capacity – Vietnam demonstration project, 2013. MMWR 2014 Jan 31;63(4):77-80.
CDC (Vernon A.) Announcement: Updated guidelines on managing drug interactions in the treatment of HIV-related tuberculosis. MMWR 2014 Mar 28;63(12):272.
Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S; the Global PETTS Investigators. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014 Jul 23. pii: ciu572. [Epub ahead of print.]
Chuke SO, Yen NT, Laserson KF, Phuoc NH, Trinh NA, Nhung DT, Mai VT, Qui AD, Hai HH, Loan le TH, Jones WG, Whitworth WC, Shah JJ, Painter JA, Mazurek GH, Maloney SA. Tuberculin skin tests versus interferon-gamma release assays in tuberculosis screening among immigrant visa applicants.external icon Tuberc Res Treat 2014; 2014:217969. doi: 10.1155/2014/217969. [Epub 2014 Mar 6.]
Coleman MS, Marienau KJ, Marano N, Marks SM, Cetron MS. Economics of United States tuberculosis airline contact investigation policies: a return on investment analysis. Travel Med Infect Dis 2014 Jan-Feb;12(1):63-71.
Cruz AT, Starke JR, Lobato MN. Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries. Curr Opin Pediatr 2013 Dec 2. [Epub ahead of print.]
Davis JL, Kawamura LM, Chaisson LH, Grinsdale J, Benhammou J, Ho C, Babst A, Banouvong H, Metcalfe JZ, Pandori M, Hopewell PC, Cattamanchi A. Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. A hypothetical trial. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1551-9. doi: 10.1164/rccm.201311-1974OC
De Beer JL, Kodmon C, Van Ingen J, Jamieson FB, Bidovec-Stojkovic U, Brown T, Cirillo DM, Cruz L, Miranda A, Dou HY, Fauville-Dufaux M, Fitzgibbon MM, Garcia De Viedma D, Groenheit R, Haanpera-Heikkinen M, Indra A, Kam KM, Kramer R, Jiang GL, Niemann S, Obrovac M, Rasmussen EM, Refregier G, Realpe T, Samper S, Sharma MK, Sougakoff W, Stakenas P, Stavrum R, Trenkler J, Wada T, Siame KK, Tafaj S, **Cowan L**, Sng LH, Seagar AL, Basu I, Rastogi N, Ferro BE, De Matos F, Kipnis A, Van Soolingen D, Supply P. Second worldwide proficiency study on variable number of tandem repeats typing of Mycobacterium tuberculosis complex. Int J Tuberc Lung Dis 2014 01 May;18(5):594-600+i.
Defang RR, Brostrom R, Ram S, Johnson E, Perman PS. Screening for tuberculosis and LTBI in diabetes patients, Pohnpei, Federated States of Micronesia. Public Health Actionexternal icon 2014 June 21; 4 (Suppl 1): S53-S55.
Duraisamy K, Mrithyunjayan S, **Ghosh S**, Nair SA, Balakrishnan S, Subramoniapillai J, **Oeltmann JE**, **Moonan PK**, Kumar AM. Does alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India. Ann Am Thorac Soc. 2014 Jun;11(5):712-8.
Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter LD, Parker M, Garrett DO, Daley CL. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 2014; 189 (1): 77-87. doi: 10.1164/rccm.201302-0365OC
Egelund EF, Weiner M, Singh RP, Prihoda TJ, Gelfond JA, Derendorf H, Mac Kenzie WR, Peloquin CA. Protein binding of rifapentine and the 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob Agents Chemother.external icon 2014 May 19. pii: AAC.01730-13. [Epub ahead of print.]
Elmore K, Nelson R, Gant Z, Jeffries C, Broeker L, Mirabito M, Roberts H. Data harmonization process for creating the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Atlas.external icon Public Health Rep 2014 Jan-Feb;129 Suppl 1:63-9.
Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP, et al. Mortality among tuberculosis patients with acquired resistance to second-line anti-tuberculosis drugs — United States, 1993-2008. Clin Infect Dis 2014. [E-pub ahead of print May 20, 2014.]
Ershova JV, Podewils LJ, Bronner E, Stockwell HG, Dlamini S, Mametja LD. Evaluation of adherence to national treatment guidelines among tuberculosis patients in three provinces of South Africa. S Afr Med J 2014 ;104(5):362-368.
Fiske CT, Yan F-X, Hirsch-Moverman Y, Sterling TR, Reichler MR, for the Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk factors for treatment default in close contacts with latent tuberculous infection. The International Journal of Tuberculosis and Lung Disease 2014 Apr 1; 18 (4): 421-427.
Girin N, Brostrom R, Ram S, McKenzie J, Kumar AM, Roseveare C. Describing the burden of non-communicable disease risk factors among adults with diabetes in Wallis and Futuna. Public Health Action 2014 01 Jun;4(Suppl 1):S39-S43.
Goodwin DJ, Mazurek GH, Campbell BH, Bohanon J, West KB, Bell JJ, Powell R, Toney S, Morris JA, Yamane GK, Sjoberg PA. Automation of an Interferon-γ release assay and comparison to the tuberculin skin test for screening basic military trainees for *Mycobacterium tuberculosis* infection. Military Medicine 2014 March; 179 (3): 333-341. doi: https://academic.oup.com/milmed/article/179/3/333/4160743external icon.
Graham SM, Sismanidis C, Menzies HJ, Marais BJ, Detjen AK, Black RE. Importance of tuberculosis control to address child survival.external icon Lancet 2014 May 3;383(9928):1605-7. doi: 10.1016/S0140-6736(14)60420-7.
Heilig CM, Feng PJ, Joloba ML, Johnson JL, Morgan K, Gitta P, Boom WH, Mayanja-Kizza H, Eisenach KD, Bozeman L, Goldberg SV. How we determined the most reliable solid medium for studying treatment of tuberculosis.external icon Tuberculosis (Edinb) 2014 May;94(3):317-22. doi: 10.1016/j.tube.2014.02.006.
Joloba ML, Johnson JL, Feng PJ, Bozeman L, Goldberg SV, Morgan K, Gitta P, Boom HW, Heilig CM, Mayanja-Kizza H, Eisenach KD. What is the most reliable solid culture medium for tuberculosis treatment trials?external icon Tuberculosis (Edinb). 2014 May;94(3):311-6. doi: 10.1016/ j.tube.2014.03.002.
Kong D, Watt JP, Marks SM, Flood JM. Timely HIV diagnosis and HIV/TB comanagement among California patients in 2008.external icon Public Health Rep 2014 Mar; 129(2):170-7.
Lam E, Nateniyom S, Whitehead S, Anuwatnonthakate A, Monkongdee P, Kanphukiew A, Inyaphong J, Sitti W, Chiengsorn N, Moolphate S, Kavinum S, Suriyon N, Limsomboon P, Danyutapolchai J, Sinthuwattanawibool C, Podewils LJ. Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008. Emerg Infect Dis 2014 Mar;20(3):408-16.
Marienau KJ, Cramer EH, Coleman MS, Marano N, Cetron MS. Flight related tuberculosis contact investigations in the United States: Comparative risk and economic analysis of alternate protocols.external icon Travel Med Infect Dis 2014 Jan-Feb;12(1):54-62. doi: 10.1016/j.tmaid.2013.09.007.
Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis [Internet] 2014 May. http://dx.doi.org/10.3201/eid2005.131037external icon. DOI: 10.3201/eid2005.131037
Medrano BA, Salinas G, Sanchez C, Miramontes R, Restrepo BI, Haddad MB, Lambert LA. A missed tuberculosis diagnosis resulting in hospital transmission. Infect Control Hosp Epidemiol 2014 May;35(5):534-7.
Mitruka K, Blake H, Ricks P, Miramontes R, Bamrah S, Chee C, Hickstein L. A tuberculosis outbreak fueled by cross-border travel and illicit substances: Nevada and Arizona. Public Health Reports 2014 Jan-Feb; 129:78-85.
Mortensen E, Hellinger W, Keller C, Cowan LS, Shaw T, Hwang S, Pegues D, Ahmedov S, Salfinger M, Bower WA. Three cases of donor-derived pulmonary tuberculosis in lung transplant recipients and review of 12 previously reported cases: opportunities for early diagnosis and prevention. Transpl Infect Dis 2014 Feb;16(1):67-75. doi: 10.1111/tid.12171.
Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, Johnson JL, Muzanyi G, Engle M, Weiner M, Janjic N, Sterling DG, Ochsner UA. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.external icon Tuberculosis (Edinb) 2014 May;94(3):187-96. doi: 10.1016/j.tube.2014.01.006.
Nasa JN, Brostrom R, Ram S, Kumar AM, Seremai J, Hauma M, Paul IA, Langidrik JR. Screening adult tuberculosis patients for diabetes mellitus in Ebeye, Republic of the Marshall Islands. Public Health Actionexternal icon 2014 June 21; 4 (Suppl 1): S50-S52.
Oeltmann JE, Click ES, Moonan PK. Using tuberculosis patient characteristics to predict future cases with matching genotype results. Public Health Actionexternal icon 2014 Mar; 4(1): 47-52.
Pang J, Teeter LD, Katz DJ, Davidow AL, Miranda W, Wall K, Ghosh S, Stein-Hart T, Restrepo BI, Reves R, Graviss EA; on behalf of the Tuberculosis Epidemiologic Studies Consortium. Epidemiology of tuberculosis in young children in the United States.external icon Pediatrics 2014 Mar; 133(3):e494-504. doi: 10.1542/peds.2013-2570.
Parija D, Patra TK, Kumar AMV, Swain BK, Satyanarayana S, Sreenivas A, Chadha VK, Moonan PK, Oeltmann JE. Impact of awareness drives and community-based active tuberculosis case finding in Odisha, India. Int J Tuberc Lung Dis 2014 Sep;18(9):1011-3.
Pascopella L, Franks J, Marks SM, Salcedo K, Schmitz K, Colson PW, Hirsch-Moverman Y, Flood J, Sayles J. Opportunities for tuberculosis diagnosis and prevention among persons living with HIV: a cross-sectional study of policies and practices at four large Ryan White program-funded HIV clinics. PLoS One. 2014 Jul 7;9(7):e101313. doi: 10.1371/journal.pone.0101313. eCollection 2014.
Podewils LJ, Alexy E, Driver SJ, Cheek JE, Holman RC, Haberling D, Brett M, McCray E, Redd JT. Understanding the burden of tuberculosis among American Indians/Alaska Natives in the U.S.: a validation study. Public Health Rep.external icon 2014 Jul;129(4):351-60.
Reilley B, Bloss E, Byrd KK, Iralu J, Neel L, and Cheek J. Death rates from human immunodeficiency virus and tuberculosis among American Indians/Alaska Natives in the United States, 1990–2009. American Journal of Public Health 2014 June (supplement); 104 (S3): S453-S459. doi: 10.2105/AJPH.2013.301746.
Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Dukes Hamilton C, Bock N, Narita M, D. Wing, Hershfield E, Goldberg SV, for the Tuberculosis Trials Consortium. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. IJTLD 2014 May 1; 18 (5): 571-580.
Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemotherexternal icon 2014 Jun;58(6):3035-3042.
Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2014; 58 (3): 381-391. doi:10.1093/cid/cit643.
Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiolexternal icon 2014 Jan 15;179(2):216-25. doi: 10.1093/aje/kwt246.
Shivaramakrishna HR, Frederick A, Shazia A, Murali L, Satyanarayana S, Nair SA, Kumar AM, Moonan PK. Isoniazid preventive treatment in children in two districts of South India: does practice follow policy? Int J Tuberc Lung Dis 2014 August 1; 18(8):919–924. http://dx.doi.org/10.5588/ijtld.14.0072external icon.
Sismanidis C, Mitchell E, Law I, Bloss E, Glaziou P. Chapter 4. Analysis of factors driving the tuberculosis epidemic. In: Understanding and Using Tuberculosis Data. Luxembourg: WHO; 2014. WHO/HTM/TB/2014.09.
Suryaprasad A, Redd JT, Ricks PM, Podewils LJ, Brett M, Oski J, Minenna W, Armao F, Vize BJ, Cheek JE. Effect of rapid influenza diagnostic testing on antiviral treatment decisions for patients with influenza-like illness: southwestern U.S, May-December 2009.external icon Public Health Rep 2014 Jul;129(4):322-7.
Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, Asis R, Reves R. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med 2014; 189 (1): 88-95.
Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, Mac Kenzie WM, Peloquin CA. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother 2014; doi:10.1093/jac/dkt483.
Weiner M, Savic RM, Mac Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JAL, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME, for the Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Ped Infect Dis 2014 3: 132-145.
Whitworth WC, Goodwin DJ, Racster L, West KB, Chuke SO, Daniels LJ, Campbell BH, Bohanon J, Jaffar AT, Drane W, Sjoberg PA, Mazurek GH. Variability of the QuantiFERON(R)-TB Gold In-Tube test using automated and manual methods. PLoS One 2014 Jan 23; 9(1): e86721.
Yakrus MA, Driscoll J, Lentz AJ, Sikes D, Hartline D, Metchock B, Starks AM. Concordance between molecular and phenotypic testing of *Mycobacterium tuberculosis* complex isolates for resistance to rifampin and isoniazid in the United States. J Clin Microbiol 2014; doi:10.1128/JCM.00417-14.
Yuen CM, Weyenga HO, Kim AA, Malika T, Muttai H, Katana A, Nganga L, Cain KP, De Cock KM. Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV – Kenya, 1998-2012.external icon PLoS One. 2014 Jun 17;9(6):e99880. doi: 10.1371/journal.pone.0099880. eCollection 2014.
Zetola NM, Modongo C, Moonan PK, Ncube R, Matlhagela K, Sepako E, Collman RG, Bisson GP. Clinical outcomes among persons with pulmonary tuberculosis disease caused by *M. tuberculosis* isolates with phenotypic DST heterogeneity. J Infect Dis 2014 Jun;209(11):1754-63. PubMed PMID: 24443546. http://jid.oxfordjournals.org/content/early/2014/01/16/infdis.jiu040.abstract?sid=a485531f-356f-418e-854c-1b72620e6551external icon
							
					
						Page last reviewed:  November 25, 2016					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosis
Basic TB Factsplus icon
How TB Spreads
Latent TB Infection and TB Disease
Signs & Symptoms
TB Risk Factors
Exposure to TB
TB Prevention
Vaccines
TB & HIV Coinfection
TB and Diabetes
TB Terms
Personal Storiesplus icon
Stories by Topic
Archived Stories
Testing & Diagnosisplus icon
Who Should be Tested
Testing for TB Infection
Testing in BCG-Vaccinated Persons
TB Screening and Testing of Health Care Personnel
Testing During Pregnancy
Diagnosing latent TB infection and TB disease
Treatmentplus icon
Deciding When to Treat Latent TB Infection
Treatment Regimens for Latent TB Infection (LTBI)
Treatment for TB Disease
Adverse Events
TB Treatment of Persons Living with HIV
TB Treatment and Pregnancy
TB Treatment for Children
Drug-Resistant TB
Researchplus icon
TB Epidemiologic Studies Consortiumplus icon
Research Projects
Publications
TB Trials Consortiumplus icon
Study Descriptions
Background
Behavioral & Social Science Research
Health Care Settingsplus icon
TB Infection Control in Health Care Settings
Resources for TB Screening and Testing of Health Care Personnelplus icon
Frequently Asked Questions
TB in Specific Populationsplus icon
Health Disparities
Asian Persons
Black or African American Persons
Hispanic or Latino Persons
Children
Pregnancy
Correctional Facilities
People Experiencing Homelessness
International Travelers
Laboratory Informationplus icon
Drug Susceptibility Testing
False-Positive Investigation Toolkit
Interim Laboratory Biosafety Guidance for XDR *Mycobacterium* tuberculosis strains
Model Performance Evaluation Program (MPEP)
Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus icon
Executive Summary
Introduction
Background on Tests for Molecular Detection of DR
General Considerations and Principles for a Molecular DR Testing Service
Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
Research Needs
General Recommendations of the Expert Panel
Communication Plan for the Report
Recommendations
References
Panel Members and CDC Participants
Appendix 1
Appendix 2
Appendix 3
The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus icon
General Considerations
General Recommendations of the Expert Panel
Recommendations to ACET, CDC, DTBE
Data & Statisticsplus icon
TB Incidence in the United States
Reported TB in the US, 2019 Surveillance Report
Trends in Tuberculosis 2019
Tuberculosis in the United States, 2019 (Slide Set)
Archived Surveillance Reports and Slide Sets
2019 State and City Report
Archived State and City Reports
Professional Resources & Toolsplus icon
Tools for Healthcare Providersplus icon
Interactive Core Curriculum on Tuberculosis: What the Clinician Should Know
Resources for TB Programsplus icon
Notice of Funding Opportunity (NOFO)
Program Evaluation
TB Centers of Excellence
TB Community Engagement Network
Publications & Productsplus icon
Patient and Public Materials
Fact Sheetsplus icon
General
Data & Statistics
Drug-Resistant TB
Infection Control & Prevention
TB in Specific Populations
Treatment
Testing & Diagnosis
Vaccines & Immunizations
Guidelinesplus icon
Control & Elimination
Drug-Resistant TB
Infection Control & Prevention
Laboratory & Genotyping
TB & HIV
TB in Specific Populations
Testing & Diagnosis
Treatment
Vaccines & Immunizations
Archived TB Guidelines
Guides & Toolkitsplus icon
Aggregate Reports
CDC TB Surveillance Training
Core Curriculum
Effective TB Interviewing for Contact Investigation
Ethnographic Guides
False-Positive Investigation Toolkit
Forging Partnerships to Eliminate TB
Guide to Application of Genotyping
LTBI: A Guide for Primary Health Care Providers
Mantoux Tuberculin Skin Testing Products
Report of Verified Case of Tuberculosis (RVCT)
Self-Study Modules
TB Contact Investigation Interviewing Skills Course
TB eDOT Toolkit
Understanding the TB Cohort Review Process
Newslettersplus icon
TB Notes, No. 1, 2021
TB Notes, No. 4, 2020
TB Notes, No. 3, 2020
TB Notes, No. 2, 2020
TB Notes, No. 1, 2020
TB Notes, No. 4, 2019
TB Notes, No. 3, 2019
TB Notes, No. 2, 2019
TB Notes, No. 1, 2019
TB Notes, No. 6, 2018
TB Notes, No. 5, 2018
TB Notes, No. 4, 2018
TB Notes, No. 3, 2018
TB Notes, No. 2, 2018
TB Notes, No. 1, 2018
TB Notes, No. 5, 2017
TB Notes, No. 4, 2017
TB Notes, No. 3, 2017
TB Notes, No. 2, 2017
TB Notes, No. 1, 2017
TB Notes, No. 5, 2016
TB Notes, No. 4, 2016
TB Notes, No. 3, 2016
TB Notes, No. 2, 2016
TB Notes, No. 1, 2016
Pamphlets, Brochures, Bookletsplus icon
Questions and Answers
Patient Education Series
Tuberculosis – Get the Facts
Tuberculosis – The Connection between TB and HIV
12-Dose Regimen for Latent TB Infection-Patient Education Brochure
Postersplus icon
Mantoux Tuberculin Skin Test Wall Chart
World TB Day
Think TB
Stop TB
Take on TB
Reports & Articlesplus icon
DTBE Authored Journal Articles
Tuberculosis Laboratory Aggregate Reports
Slide Setsplus icon
Introduction to Tuberculosis
Epidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016
Self-Study Modules on Tuberculosis, 1-5 Slide Sets
The Tuberculosis (TB) in Correctional Settingsplus icon
Facilitator Guide
Introduction to TB Genotyping
Epidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017
Prevention and Control of Tuberculosis in Correctional and Detention Facilities
Guidelines for Preventing the Transmission of M. TB in Health care Settings
Investigation of Contacts of Persons with Infectious TB
Epidemiology of Pediatric Tuberculosis in the United States
Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection
Electronic Tools & Resources
Web-Based Courses & Webinarsplus icon
TB 101 for Health Care Workersplus icon
TB 101
Interactive Core Curriculum
Content Syndication
Infographicsplus icon
Social Media Graphics
Customizable Take on TB Infographic with Instructions
Events
World TB Dayplus icon
Resources
U.S. TB Championsplus icon
2021 CDC U.S. TB Elimination Champions
2020 CDC U.S. TB Elimination Champions
2019 CDC U.S. TB Elimination Champions
2018 CDC U.S. TB Elimination Champions
2017 CDC U.S. TB Elimination Champions
2016 CDC U.S. TB Elimination Champions
News & Events
History
Featuresplus icon
TB Risk Factors
Treating Latent TB Infection with Short-Course Regimens
World Tuberculosis (TB) Day 2021
World Tuberculosis (TB) Day 2020
Linksplus icon
State TB Control Offices
About Usplus icon
Mission Statement and Activitiesplus icon
DTBE Strategic Plan
National TB Program Objectives
Organization Chart
Advisory Groupsplus icon
Federal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue